Morgan Stanley Starts Rocket Pharmaceuticals (RCKT) at Overweight, Sees Over 100% Upside
Tweet Send to a Friend
(Updated - February 1, 2023 6:30 AM EST)
Morgan Stanley analyst Michael E Ulz initiates coverage on Rocket Pharmaceuticals ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Morgan Stanley analyst Michael E Ulz initiates coverage on Rocket Pharmaceuticals ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
